NCT05566834 - Minnelide™ Capsules Alone and in Combination With Paclitaxel in Advanced Gastric Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 2, 2020

Primary Completion Date

June 30, 2024

Study Completion Date

November 30, 2024

Conditions

Gastric Cancer

Interventions

DRUG

Minnelide

at the MTD dose level established for monotherapy or combination to confirm safety. With a sample of 12 patients, the probability is \> 80% that a serious adverse event with at least a 16% incidence will be detected.

Trial Locations (1)

135-710

RECRUITING

Samsung Medical Center, Soeul